First da­ta for Lil­ly's RNA treat­ment for heart dis­ease point to long-term dura­bil­i­ty in tiny group of pa­tients

PHILADEL­PHIA — Eli Lil­ly’s in­ves­ti­ga­tion­al RNA si­lenc­ing drug low­ered lev­els of lipopro­tein(a) in an ear­ly-stage study. El­e­vat­ed lev­els of Lp(a) have been as­so­ci­at­ed with a high­er risk of heart dis­ease, heart at­tack and stroke.

In 48 adult par­tic­i­pants with el­e­vat­ed Lp(a) lev­els who did not have heart dis­ease, re­searchers test­ed six dif­fer­ent dos­es of a one-time in­jec­tion of lep­o­disir­an. The dos­es ranged from 4 mg to 608 mg and in­clud­ed a place­bo. At the high­est dose, which was giv­en to six peo­ple, Lp(a) lev­els fell be­low what re­searchers were able to re­li­ably mea­sure af­ter one month and stayed that low un­til the nine-month mark. At near­ly one year, the par­tic­i­pants who re­ceived the high­est dose had Lp(a) lev­els that were 94% low­er than when they start­ed the tri­al.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.